With $9.7 billion acquisition, Novartis bets that heart drugs are coming back
Novartis' deal for The Medicines Company represents a new chance for a type of cholesterol-lowering drug — and for its CEO.
Cambiar nuestra forma de vivir para cambiar el mundo
Hace 18 minutos
.png)
No hay comentarios:
Publicar un comentario